Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps9117
Abstract: TPS9117Background: Afatinib and pembrolizumab have demonstrated improvements in the outcomes of pts with SCC of the lung and are approved as monotherapy. Afatinib is a selective and irreversible Er... read more here.
Keywords: combination pembrolizumab; pembrolizumab patients; patients pts; afatinib combination ... See more keywords